Skip to main content

Table 3 Comparative overview of the literature focusing on brachytherapy boost for anal canal carcinoma according to the brachytherapy dose-rate

From: Interstitial high-dose rate brachytherapy as boost for anal canal cancer

Authors (Year) # pts* Median FU (months) Dose Rate Median BT dose (Gy) LR (%) OS (%) Colostomy Late toxicity ≥ G3 [%]
      LRR (%) LCR (%)   CR % CFS %  
Peiffert et al. (1997) [16] 101/118 72 LDR 21.5 N/A 60 (5 y) 9 - 13.5
Papillon et al. (1989) [17] 221 > 36 LDR 20 to 30 N/A 69.2 (3 y) 2.7 - N/A
Wagner et al. (1994) [18] 96 35.5 to 51.7** LDR 20.2** 16.6 - 64 (5 y) N/A 9.25
Gerard et al. (1999) [19] 19 N/A PDR 10 to 25 5,2 - 100 (1 y) 0 - 0
Bruna et al. (2006) [20] 71 28.5 PDR 17.8** N/A 90 (2y) - 89 (2 y) N/A  
Roed et al. (1996) [10] 17 11.3 PDR 28.85 23.5 - N/A 47 - N/A
Kapp et al. (2001) [21] 39 31 HDR 6 to 12***   81 (3 y) 80 (3 y DSS) - 78 (3 y) 7.6
76 (5 y) 76 (5 y DSS) 73 (5 y)
Vordermark et al. (2001) [5] 20 52.8** HDR 5 to 12 5 - 84 (5 y) - 68.9 (5 y) N/A
Doniec et al. (2006) [23] 50 34 HDR 8 to 12 N/A 74 (5 y) 4 - N/A
Oehler-Jänne et al. (2007) [24] 34 60** HDR 14 10.3 (5y) - 66 (10 y) 15 - N/A
Saarilahti et al. (2008) [25] 29/59 51 HDR 12 N/A N/A N/A N/A
Kapoor et al. (2013) [15] 16 41 HDR 18 (6f) - 87.5 (2 y) N/A N/A 0
21 (7f) N/A
Falk et al. (2014) 28 27.5 HDR 12 (3f) - 83 (2 y) 87.7 - 75.1 (2 y) 7.1
  1. *If ratio, number of patients treated by brachytherapy boost/total number of patients treated.
  2. **Mean.
  3. ***6 Gy during the EBT period and 6 Gy after EBT in case of partial response.
  4. # pts: number of patients; FU: follow-up; BT: brachytherapy; LR: local recurrence; LRR: local recurrence rate; LCR: local control rate; OS: overall survival; CR: colostomy rate; CFS : colostomy free survival; LDR: low-dose rate brachytherapy; PDR: pulsed dose rate brachytherapy; HDR: High-dose rate brachytherapy; NA: non-applicable; DSS: disease specific survival.